Chinese switch hurts Bayer

An “unexpected” move by the China Food and Drug Administration (CFDA) to reverse-switch two of its leading OTC products, in combination with “persistently weak business development in the US”, caused Bayer’s Consumer Health sales to fall by 2.9% to €5.86 billion in 2017, the German company reported.

An “unexpected” move by the China Food and Drug Administration (CFDA) to reverse-switch two of its leading OTC products, in combination with “persistently weak business development in the US”, caused Bayer’s Consumer Health sales to fall by 2.9% to €5.86 billion in 2017, the German company reported.

More from Earnings

More from Business

A ‘Once-In-A-Lifetime Experience’ – Carlton Lawson On Kenvue’s Spin Out Journey

 
• By 

Kenvue's EMEA and LATAM head Carlton Lawson reflects on the firm's 18 months of independence, pointing to significant investments and operational improvements as key milestones on its spin out journey so far.

P&G: Use Of AI For Ad Development, Targeting Provides ‘Fuel’ For Reinvestment – CFO

 

The Procter & Gamble Co.’s use of AI in advertising is yielding considerable savings every year that it is able to invest in reaching households currently underserved by its products, says CFO Andre Schulten.

FDA Issuing Facility Inspection Requests Under MoCRA, While Slow On Enforcement (So Far)

 

The US FDA has generally not sent out enforcement letters to stakeholders of the Modernization of Cosmetics Regulation Act, but that doesn’t mean it’s not happening, says Amin Wasserman Gurnani, LLP attorney Angela Diesch, during a 19 November webinar hosted by Global Victoria, the trade facilitation agency for the state of Victoria in Australia.